IMMIX BIOPHARMA INC.

Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting

09 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer

07 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

13 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached

06 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting

28 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

20 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors

19 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

14 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

13 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

12 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher

11 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26

25 Oct 2022 08:00:32 By Nasdaq GlobeNewswire

ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

18 Oct 2022 08:00:02 By Nasdaq GlobeNewswire

ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

07 Sep 2022 12:05:34 By Nasdaq GlobeNewswire

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

20 May 2022 08:47:35 By Nasdaq GlobeNewswire

Immix Biopharma Announces Share Repurchase Program

09 May 2022 08:00:02 By Nasdaq GlobeNewswire

ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022

05 Apr 2022 09:30:00 By Nasdaq GlobeNewswire

Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022

07 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease

22 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022

01 Feb 2022 09:30:00 By Nasdaq GlobeNewswire